RxDoctor Payments Data

Philip Totonelly, MD

Interventional Cardiology · Fishkill, NYNPI 1821180399

Payments from drug & device makers

$371in general payments, 2019–2025

Across 18 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$151
  • Lilly USA, LLC$68
  • Regeneron Healthcare Solutions, Inc.$44
  • Johnson & Johnson$34
  • Medtronic$28
  • Amgen$28
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$33991%
  • Education$329%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$371 in reported general payments places this provider in the 0th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$170,000
Medicare patients
127
Services billed
928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$46,258
XareltoRivaroxaban47$42,423
JardianceEmpagliflozin30$32,742
MounjaroTirzepatide13$13,858
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide97$3,626
Valsartan59$1,870
Atorvastatin Calcium104$1,654
Levothyroxine Sodium30$1,033
Icosapent Ethyl13$814
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$794
Metoprolol Succinate39$788
Rosuvastatin Calcium50$781
Bumetanide27$752
Cephalexin44$591
Omeprazole26$542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$151$46,25835 claims
Johnson & JohnsonXarelto$34$42,42347 claims
Lilly USA, LLCMounjaro$68$13,85813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Fishkill

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →